HRD is a clinically important feature because HRD-positive HGSOC can be sensitive to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors. Existing genomic tests examine alterations in DNA-repair genes and genome-wide patterns of genomic instability. The study notes that these assays can be variable, costly and time-consuming, and that their prediction of PARP-inhibitor response is less robust in BRCA1/2-wild-type cancers than in cancers with germline or somatic BRCA1/2 mutations. HRDPath was designed to use pathology slides that are routinely produced during diagnosis, without adding a molecular assay. Its output includes both binary HRD status and a continuous prediction intended to correspond to the genomic HRD score.

The main development cohort contained 720 diagnostic slides from 152 patients, including 145 patients with HGSOC and seven with other ovarian cancers. HRD status was assigned with the HRDetect whole-genome sequencing algorithm, which labeled 82 patients HRD-positive and 70 HRD-negative. The training set comprised 493 slides from 117 patients, and the held-out test set contained 138 slides from 29 patients. All slides from a given patient were assigned exclusively to one partition, preventing patient-level data leakage. Two additional cohorts, the TCGA ovarian collection and the PTRC-HGSOC collection, provided independent validation using labels based on a different genomic approach involving loss of heterozygosity, large-scale translocations and telomeric allelic imbalance.

Because a whole-slide image is far larger than the fixed-size inputs used by many image classifiers, HRDPath divides each slide into 1,024-pixel patches, filters background and normalizes staining variation. The remaining patches are converted into numerical features with RetCCL, a self-supervised representation model trained on 32,000 pan-cancer whole-slide images. The architecture has three complementary streams. Dual-Stream Multiple Instance Learning identifies patches that appear informative and pools them into a slide representation. A global Vision Transformer processes the full patch set with self-attention to capture context across the slide. A third local transformer analyzes fixed-size windows centered on regions selected by the first stream, with absolute positional encoding used to preserve spatial relationships.

Information from all slides belonging to a patient is then combined by a patient-level transformer, allowing the model to relate findings across primary tumors and metastatic deposits. The final embedding feeds a multi-task prediction head trained jointly with binary cross-entropy for HRD classification and mean-squared error for continuous HRD-score regression. In ablation tests, the complete model achieved an AUC of 0.846, compared with 0.769 when local windows were used without absolute positional encoding and 0.745 for a more restricted variant. The results indicate that the gain came from the interaction among global context, instance selection and spatially constrained attention rather than from one component alone. Under the same patient-level evaluation framework, HRDPath outperformed comparison systems including DeepHRD, ZoomMIL, CLAM variants and a UNI-based feature pipeline.

Multiple-slide aggregation improved reliability. Predictions were generally consistent among different slides from the same patient, and accuracy exceeded 0.950 when at least six slides were included, corresponding to sensitivity of 0.910 and specificity of 1.000 in that analysis. Including at least two primary-site slides produced average sensitivity of 0.930 and specificity of 0.890, while using only one primary slide reduced sensitivity to a range of 0.769–0.869 and left specificity high. The researchers also developed a patient-level agreement measure that could flag predictions supported by at least 70% of constituent slides. Anatomical diversity alone did not add an independent benefit when adequate primary-site sampling was available. A perfectly separating result across three anatomical locations involved only 13 patients and remains exploratory.

Transfer tests showed that the approach could retain useful performance outside its development cohort. When HRDPath was trained on the TCGA dataset, it reached an AUC of 0.847, with 71.4% specificity and 78.6% sensitivity. In three-fold few-shot experiments on TCGA and PTRC, fine-tuning with only one or two example images per class produced an AUC as high as 0.823, with 70.0% specificity and 98.1% sensitivity. Stain normalization was important for cross-dataset transfer. The model also performed well on abdominal metastases despite having no abdominal slides in the training set, although performance was lower in other pelvic samples and when trained solely on primary tumors. A related model, HRDPath-BRCA, predicted BRCA1/2-associated alterations, including BRCA1 methylation, with an AUC of 0.800, 95.2% specificity and 60.0% sensitivity.

Attention analysis and single-cell morphology measurements provided model-interpretability insights and identified associations between HRD status and tissue features; they did not establish a causal biological mechanism. Although HRDPath received no tumor-segmentation labels, high-attention patches tended to overlap with neoplastic regions, with a mean patch-wise Pearson correlation of 0.34 between model attention and neoplastic-cell proportion. Within highly attended regions, HRD-positive tumors had more rounded and less elongated nuclei, greater local cell density and lower variability in nuclear roundness and area than HRD-negative tumors. The effect sizes were small, with Cohen’s d between 0.225 and 0.262 for the principal nuclear comparisons, and the distributions overlapped substantially. Models based only on aggregated morphology reached a maximum cross-validated AUC of 0.593, showing that the spatial and contextual information used by HRDPath was not reducible to a few simple cellular measurements.

The researchers further grouped highly attended regions into eight visual VAttentionClusters. Four were dominated by neoplastic cells, while others represented fibrotic or stromal tissue, adipose tissue and infarcted tissue. One neoplastic cluster was enriched in HRD-negative cancers, whereas another was enriched in HRD-positive cancers and particularly in tumors with BRCA1/2 alterations. These clusters also varied by anatomical site, suggesting that some phenotypes associated with HRD were shared between primary and metastatic tumors while other microenvironmental features were location-specific. Patient-level analyses found that some neoplastic clusters appeared in both tubo-ovarian and omental samples from the same patient. In exploratory survival analyses, image-based false-positive and false-negative classifications were associated with different survival patterns from genomically concordant cases, but the study did not show that image predictions caused the outcomes or that they improve treatment selection.

Several limitations constrain translation. The work was retrospective, and the researchers were not blinded to data allocation or outcome assessment. The principal cohort came from a single center, while the public validation datasets used different HRD definitions and included a highly imbalanced PTRC cohort with only five HRD-negative patients. The study excluded cases lacking matched molecular annotations or digitized slides, did not impute missing data and did not use treatment information as a predictor. HRDetect is well validated but is not approved by the US Food and Drug Administration. Broader evaluation with multiple clinical HRD assays, more diverse populations and larger balanced cohorts will be needed. The code was not publicly available because of institutional intellectual-property and commercialization processes. The findings therefore support HRDPath as a digital-biomarker candidate and a means of extracting information from routine pathology, rather than as a clinically validated replacement for genomic testing.

Subject of Research: Deep-learning prediction of homologous recombination deficiency from HGSOC histopathology images

Article Title: HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images

Article References: Wu, C.-I., Banda, K., Arora, R., Soong, T. R., Radke, M., Dillon, M., Nik-Zainal, S., Swisher, E. M., & Sailem, H. Z. (2026). HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images. Nature Communications, 17(1), Article 10870. https://doi.org/10.1038/s41467-026-78430-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78430-y

Keywords: HRDPath, HGSOC, homologous recombination deficiency, deep learning, computational pathology, whole-slide images, digital biomarkers, morphology, medical artificial intelligence, BRCA1/2, explainable, multi-model

The study, led by Litian Chen and colleagues at The First Affiliated Hospital of Wenzhou Medical University, centers on a reanalysis of the public dataset GSE300897, which contains 19,156 annotated cells drawn from nine treatment-naive high-grade serous ovarian carcinoma biopsy libraries. Four of those libraries came from patients whose disease proved chemotherapy-refractory and five from patients who responded. Rather than pooling cells and treating each one as an independent observation, the team kept the library, and by extension the patient, as the unit of comparison, a methodological choice that guards against the statistical inflation that has plagued some single-cell analyses.

The researchers scored each library against a set of predeclared gene panels covering type-I interferon signaling, hypoxia, epithelial-to-mesenchymal transition, cytotoxicity, immune-checkpoint genes, macrophage-like programs, extracellular matrix genes, and a DNA-damage and drug-handling program. Program scores were computed as the mean of log-normalized expression across panel genes, with the epithelial-to-mesenchymal balance defined as the mesenchymal score minus the epithelial score. When the refractory and sensitive libraries were compared, no cancer-cell program passed Benjamini-Hochberg correction at a false-discovery threshold of 0.05, a sobering result the authors report plainly rather than burying.

What survived was direction. Refractory libraries showed a lower type-I interferon score, averaging minus 0.15 log1p(CP10k) units relative to sensitive tumors, and a lower epithelial-to-mesenchymal transition balance of minus 0.16, alongside a small increase in hypoxia of plus 0.05. The interferon signal is biologically provocative. Type-I interferon signaling in tumor cells has been shown in prior work to contribute to the efficacy of chemotherapy, so a tumor that enters treatment with a muted interferon program may be a tumor that is already predisposed to ignore the drug. Hypoxia, meanwhile, is a long-recognized accomplice of chemoresistance across solid tumors.

To place these small-cohort patterns in a wider frame, the team turned to The Cancer Genome Atlas Ovarian Cancer collection, analyzing 421 unique primary tumors, of which 419 were evaluable for survival analysis. Counts were transformed and standardized, and the same gene panels were applied. In age- and stage-adjusted Cox models restricted to evaluable stage IIIC and IV cases, none of the six displayed program scores reached statistical significance after false-discovery correction. Interferon tertiles did separate nominally on Kaplan-Meier analysis, with a log-rank p value of 0.029, but when interferon was modeled as a continuous variable the association dissolved, yielding a hazard ratio of 0.96 per standard deviation and an adjusted q value of 0.927.

The authors are explicit about what this means. The Cancer Genome Atlas provided context, not validation. It lacks the chemotherapy-response annotation that defines the refractory-versus-sensitive question, so it cannot independently confirm or refute the single-cell findings. The nominal survival separation by interferon tertile is the kind of result that invites over-interpretation, and the paper resists that temptation, framing the cohort analysis as descriptive scaffolding around the central, underpowered single-cell comparison.

One of the more unusual components of the study is a single-case radiogenomic illustration. The TCGA case TCGA-24-1423 links a multiparametric MRI examination, comprising 23 MR series and 723 DICOM instances from a 1.5-tesla abdominal-pelvic study, to a matched tumor RNA-seq barcode. The imaging display spans pre-contrast, post-contrast, and delayed T1 VIBE sequences, axial T2 HASTE, diffusion-weighted imaging, and apparent diffusion coefficient maps. In the paired transcriptome, the interferon program sat at the 86.8th percentile of the TCGA-OV distribution, with IFIT1 at the 87.5th percentile and MX1 at the 93.7th, while hypoxia and epithelial-to-mesenchymal balance hovered near the cohort midpoint. The authors stress that one barcode-matched case demonstrates feasibility, nothing more, and cannot establish an imaging phenotype or support patient-level prediction.

The fourth leg of the study is a laboratory experiment in two established ovarian cancer cell lines, OVCAR-3 and Caov-3, exposed to 5 micromolar cisplatin for 24 hours. Quantitative PCR with GAPDH as the reference showed that acute cisplatin exposure reduced expression of the interferon-stimulated genes IFIT1 and MX1 while increasing the EMT-related gene SNAI1 and the hypoxia-associated gene HIF1A in both lines, with all comparisons significant after Holm adjustment. In OVCAR-3 cells, IFIT1 fell to 0.55-fold of vehicle levels and HIF1A rose to 1.64-fold; Caov-3 cells moved in the same direction. The authors are careful to note that this assay models an acute drug response, not the pretreatment state that distinguishes refractory patients, and that SNAI1 as a single marker is not equivalent to the multigene epithelial-to-mesenchymal balance score used in the transcriptomic work.

The limitations section is unusually candid and deserves attention. Nine libraries is a very small cohort, and chemotherapy status is confounded with anatomical sampling location, since all three omental biopsies belonged to the sensitive group. The response comparisons are secondary analyses of public annotations and cannot eliminate unmeasured clinical or sampling confounding. The MRI component is a single case. The cell-line experiment covers two lines, one dose, one exposure duration, and four biological replicates per condition. Each of these constraints narrows what the study can claim, and the authors draw those boundaries themselves rather than leaving the reader to guess.

What emerges is a hypothesis-generating portrait of chemotherapy refractoriness in high-grade serous ovarian carcinoma: tumors that ultimately fail first-line therapy tended, in this small sample, to carry quieter interferon programs, a shifted epithelial-to-mesenchymal balance, and a whisper more hypoxia, with laboratory perturbation offering directionally compatible evidence that cisplatin itself pushes cells along the same axes. The value of the paper lies as much in its discipline as in its findings. In a field where single-cell signals are easily oversold and radiogenomic associations easily overdrawn, this team has produced a transparent, conservatively analyzed triangulation that nominates interferon signaling, hypoxia, and cell-state plasticity for rigorous testing in larger, response-annotated, imaging-linked cohorts, while explicitly declining to offer clinicians a test they cannot yet trust.

Subject of Research: Transcriptional heterogeneity associated with primary chemotherapy refractoriness in high-grade serous ovarian carcinoma

Article Title: Chemotherapy-refractory high-grade serous ovarian carcinoma: single-cell findings, TCGA-OV transcriptomic context, and a single-case MRI–transcriptome illustration

Article References: Chen, L., Fu, P., Wu, S., Chen, B., & Wen, X. (2026). Chemotherapy-refractory high-grade serous ovarian carcinoma: single-cell findings, TCGA-OV transcriptomic context, and a single-case MRI–transcriptome illustration. Frontiers in Genetics, 17, Article 1943981. https://doi.org/10.3389/fgene.2026.1943981

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1943981

Keywords: high-grade serous ovarian carcinoma, chemotherapy refractoriness, single-cell RNA sequencing, type-I interferon, hypoxia, epithelial-to-mesenchymal transition, TCGA-OV, radiogenomics, MRI, cisplatin, RT-qPCR, tumor microenvironment

The study, published in Holistic Integrative Oncology, compared two maintenance strategies in patients with primary high-grade serous ovarian carcinoma who had responded to first-line platinum-based chemotherapy. One group received Olaparib alone, a PARP inhibitor taken orally twice daily, while the other received Olaparib combined with Bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor and is delivered intravenously every three weeks. The researchers followed 214 eligible patients drawn from an initial pool of 878 ovarian carcinoma diagnoses, dividing them into a monotherapy group of 139 patients and a combination group of 75, treated between July 2018 and April 2025.

The biological logic behind combining these two agents is elegant. PARP inhibitors such as Olaparib exploit a vulnerability known as synthetic lethality: many high-grade serous ovarian tumors carry defects in homologous recombination, the molecular machinery that repairs dangerous DNA breaks, often because of mutations in the BRCA1 or BRCA2 genes. When PARP-mediated repair is also blocked, cancer cells accumulate lethal DNA damage and die. Bevacizumab attacks from an entirely different angle, starving tumors of their blood supply by neutralizing VEGF signaling. Preclinical work has long suggested these pathways are complementary, because VEGF-driven angiogenesis and PARP-mediated DNA repair both sustain tumor survival, and blocking them together may produce effects neither drug achieves alone.

That synergy was validated in the landmark PAOLA-1 trial, which showed that Olaparib plus Bevacizumab as first-line maintenance extended progression-free survival compared with Bevacizumab alone, particularly in patients whose tumors were homologous recombination deficient. The combination subsequently entered major clinical guidelines, including those of the National Comprehensive Cancer Network. But randomized trials enroll carefully selected patients under idealized conditions, and oncologists have lacked robust real-world evidence on how the two strategies compare head to head in routine practice, where patients carry comorbidities, varied performance statuses, and socioeconomic realities that trials often exclude. The new study was designed to fill exactly that gap.

The headline result is, on the surface, a null finding. Across the entire cohort of 214 patients, Kaplan-Meier analysis revealed no statistically significant difference in progression-free survival between the two regimens, with a log-rank P value of 0.82. Median progression-free survival was 20.3 months for patients on Olaparib alone and 20.4 months for those on the combination, a difference of barely three weeks. Overall survival likewise showed no significant separation between the groups, with a log-rank P value of 0.40. For an unselected population of women with high-grade serous ovarian carcinoma, adding Bevacizumab to Olaparib maintenance did not appear to delay progression or extend life.

But the story changed dramatically when the researchers stratified patients by molecular biomarker. Among the subgroup with documented BRCA mutations, progression-free survival remained comparable between the two treatments, with a log-rank P value of 0.79. Overall survival, however, told a different story: patients receiving the Olaparib-Bevacizumab combination experienced a statistically significant improvement in overall survival compared with those on monotherapy, with a log-rank P value of 0.01. In a disease where the median overall survival has historically hovered in the range of a few years, a survival advantage confined to a biomarker-defined subgroup is precisely the kind of signal that reshapes treatment algorithms.

The mechanistic explanation for this divergence is intriguing. Because progression-free survival was similar in the BRCA-mutated subgroup, the survival benefit cannot simply reflect delayed initial progression. Instead, the authors suggest that the combination may alter the natural history of the disease after progression, perhaps producing more durable clinical control or enhancing the effectiveness of subsequent lines of therapy. One plausible mechanism involves vascular normalization: by pruning the chaotic, leaky vasculature that tumors build, Bevacizumab may temporarily normalize blood flow within the tumor, improving drug delivery and reducing hypoxia, a well-known driver of resistance to PARP inhibition. In BRCA-mutated tumors, which are already exquisitely sensitive to PARP blockade, this vascular effect may amplify the DNA-damaging pressure on cancer cells in ways that translate into longer life.

The safety data provide reassurance that this added benefit does not come at the cost of added toxicity, at least for the toxicities examined. The researchers focused on clinically relevant adverse events, including hematologic toxicities such as anemia, neutropenia, and thrombocytopenia, as well as hepatotoxicity and nephrotoxicity. The incidence rates of these events were similar between the two treatment groups, with no statistically significant differences observed. Median duration of maintenance therapy was 7.05 months in the monotherapy group and 9.73 months in the combination group, suggesting that patients tolerated the dual regimen well enough to remain on treatment for longer periods.

The study also probed whether other molecular features might predict differential benefit, examining patients with TP53 mutations as determined by immunohistochemistry on primary surgical specimens. In that subgroup, neither progression-free survival nor overall survival differed significantly between the two regimens, with log-rank P values of 0.25 and 0.76 respectively. A multivariate Cox proportional hazards analysis incorporating age, FIGO stage, residual disease status, and key immunohistochemical markers found no factor independently associated with overall survival, underscoring how difficult prognostication remains in this heterogeneous disease and how much the field still depends on biomarker-driven subgroup analysis.

The authors are candid about the limitations of their work. As a single-institution retrospective cohort study, it is vulnerable to selection bias and unmeasured confounding, and the modest sample size, particularly within the BRCA-mutated subgroup, limits statistical power. Certain baseline characteristics, such as age, were not fully balanced between the treatment groups, and given that BRCA status is itself a strong predictor of PARP inhibitor response, residual confounding cannot be excluded even with multivariate adjustment. These caveats mean the survival signal should be treated as hypothesis-generating rather than definitive, and the researchers call for prospective studies with larger, well-annotated cohorts and comprehensive biomarker profiling to validate the finding.

Even with those caveats, the clinical message is clear and potentially practice-changing. For women with high-grade serous ovarian carcinoma who lack BRCA mutations, Olaparib monotherapy appears to deliver equivalent benefit as first-line maintenance, sparing patients the inconvenience, cost, and infusion schedule of added Bevacizumab without sacrificing survival. For the clinically critical subset harboring BRCA mutations, however, the combination regimen is associated with a significant overall survival advantage, reinforcing and extending the evidence from PAOLA-1 and supporting the continued use of biomarker stratification when selecting maintenance therapy. In an era where precision oncology increasingly determines who benefits from which drug, this study is a textbook example of why the question is no longer simply whether a treatment works, but for whom.

Subject of Research: Comparison of Olaparib monotherapy versus Olaparib plus Bevacizumab as first-line maintenance therapy in primary high-grade serous ovarian carcinoma

Article Title: Comparison of survival outcomes of Olaparib or Olaparib combine with Bevacizumab in patients with primary high-grade serous ovarian carcinoma

Article References: Cai, L., Fang, H., Zhang, X., Wang, Z., Wang, J., Fang, C., & Wu, N.-Y. Y. (2026). Comparison of survival outcomes of Olaparib or Olaparib combine with Bevacizumab in patients with primary high-grade serous ovarian carcinoma. Holistic Integrative Oncology, 5(1), Article 23. https://doi.org/10.1007/s44178-026-00232-5

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00232-5

Keywords: ovarian cancer, high-grade serous ovarian carcinoma, Olaparib, Bevacizumab, PARP inhibitor, BRCA mutation, maintenance therapy, overall survival, progression-free survival, biomarker-driven therapy, anti-angiogenic therapy, real-world evidence